The nation of Zimbabwe has turned down a major American health deal valued at 367 million US dollars (272 million pounds) spanning five years over the United States' demand for sensitive data.
The decision became public after a official document from December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "skewed".
An official representative later stated that the US was demanding access to health data for scientific study and commercial purposes but was not willing to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for continued dialogue to secure a agreement acceptable to both sides so the nation's vital HIV treatment initiative can continue.
Broader Implications
This rejection comes after a similar case in neighbouring Kenya, where a high court suspended a related deal with the US following concerns were filed about the security of citizens' medical information.
Since returning to office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen aid for the US government, but Trump claimed its spending was "inefficient" and his administration was pursuing direct bilateral agreements to enhance openness and accountability.
As per statements, Sixteen African countries have to date signed similar agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," his statement read.
"Effectively, our nation would provide the basic resources for medical research with no assurance that the end products would be available to our citizens if a future health crisis arise."
National Interest and International Frameworks
He also noted that the American exit from the global health body and its pursuit of bilateral health agreements were undermining frameworks previously set up through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage future pandemics.
"This mechanism is designed to ensure that when a country provides its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how subsequent co-operation might be arranged in a way that respects the sovereignty and interests of both nations."
Medical Community Response
Medical experts stated it acknowledged the official position, but recommended that talks must proceed since much of the country's HIV programmes were funded by international support.
"If specific concerns arise, such as those relating to information security or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group said.
The halted deal highlights the ongoing debate between accepting much-needed international aid and safeguarding a country's data in an ever more data-driven world.